Company intelligence / Profile preview

Kedrion Biopharma

Castelvecchio Pascoli, Tuscany, Italykedrion.it ↗

Ownership: Private
Employees: ~5200
Development stage: Commercial

Overview

Kedrion is a global leader in the collection and fractionation of human plasma to produce 38 vital medicines distributed worldwide. The company has FDA-approved products for rare diseases such as congenital plasminogen deficiency, with ongoing R&D focused on orphan drugs for ultra‐rare conditions. In 2024, it reported +10% growth and continues to expand its product portfolio and manufacturing capabilities.

Therapeutic areas: Women's HealthHematologyImmunologyNeurology
Modalities: Plasma-derived therapies/products
Industry: Biotech

Drug pipeline

14 assets

rabies immune globulin (human)

Approved

13 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kedrion Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kedrion Biopharma.

Explore the full profile